

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2007 (16.08.2007)

PCT

(10) International Publication Number
WO 2007/091106 A3

(51) International Patent Classification:

A61K 31/343 (2006.01) A61K 31/4365 (2006.01)
 A61K 31/4184 (2006.01) A61K 31/437 (2006.01)
 A61K 31/4192 (2006.01) A61K 31/4439 (2006.01)
 A61K 31/4196 (2006.01) A61K 31/4525 (2006.01)
 A61K 31/423 (2006.01) A61K 31/454 (2006.01)
 A61K 31/4245 (2006.01) A61K 31/4709 (2006.01)
 A61K 31/426 (2006.01) A61K 31/404 (2006.01)
 A61K 31/4355 (2006.01)

(21) International Application Number:

PCT/GB2007/050055

(22) International Filing Date: 9 February 2007 (09.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0602768.4 10 February 2006 (10.02.2006) GB
 0614690.6 24 July 2006 (24.07.2006) GB
 0619281.9 29 September 2006 (29.09.2006) GB
 0623983.4 30 November 2006 (30.11.2006) GB

(71) Applicant (for all designated States except US): SUMMIT CORPORATION PLC [—/GB]; 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WYNNE, Graham Michael [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). WREN, Stephen Paul [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). JOHNSON, Peter David [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). PRICE, Damien [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). DE MOOR, Olivier [FR/GB]; Vastox Plc, 91

Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). NUGENT, Gary [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). TINSLEY, Jonathan Mark [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). STORER, Richard [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). MULVANEY, Andrew [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). PYE, Richard Joseph [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). DORGAN, Colin Richard [GB/GB]; Vastox Plc, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).


(74) Agent: WRIGHT, Robert Gordon McRae; Elkington And Fife LLP, Prospect House, 8 Pembroke Road, Sevenoaks, Kent TN13 1XR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY



(1)

(57) Abstract: There are disclosed compound of Formula (1): A₁, A₂, A₃ and A₄ which may be the same or different, represent N or CR₁, X is a divalent group selected from O, S(O)_n, C=W, NR₄, NC(=O)R₅ and CR₆R₇, W is O, S, NR₂₀, Y is N or CR₈, one of R₄, R₅, R₆, R₈, R₉ and NR₂₀ represents - L - R₃, in which L is a single bond or a linker group, additionally, R₁, R₃ - R₉, which may be the same or different, independently represent hydrogen or a substituent and R₂₀ represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkanoyl, optionally substituted aroyl, NO₂, NR₃₀R₃₁, in which R₃₀ and R₃₁, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R₃₀ and R₃₁ may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A₁ - A₄ each represent CR₁, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR₆R₇, R₆ and R₇, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.



WO 2007/091106 A3



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
6 March 2008